Replies to post #217336 on Biotech Values

[DewDiligence]

AZN—PACIFIC study in Stage-III NSCLC shows statsig OS benefit:

https://www.astrazeneca.com/media-centre/press-releases/2018/imfinzi-significantly-improves-overall-survival-in-the-phase-iii-pacific-trial-for-unresectable-stage-iii-non-small-cell-lung-cancer-25052018.html

The HR for OS has not been disclosed, pending presentation at a medical conference.

The FDA approved AZN’s Imfinzi in Stage-III NSCLC in Feb 2018 (#msg-138626896) based on PACIFIC’s statsig PFS for chemo/Imfinzi (sequentially rather than in combination) vs chemo alone. Today is the first time PACIFIC’s OS outcome was reported.